Le Lézard
Classified in: Health, Science and technology, Business
Subjects: VEN, SBS

Enable Injections' First Closing of Series B Round to Include a New Investor


CINCINNATI, Oct. 25, 2018 /PRNewswire/ -- Enable Injections, Inc., a combination products company developing advanced wearable devices for subcutaneous delivery of biologics and other high volume therapeutics, completed a first closing of a Series B round that will raise up to $50M, led by Sanofi.

The enFuse connected wearable large-volume drug delivery platform-HIPAA compliant adherence monitoring

Previous investors ORI Healthcare Fund (ORI Fund), CincyTech, Cincinnati Children's Hospital, Cintrifuse, Ohio Innovation Fund, Cleveland Clinic and key private investors also participated in the financing.

"We are delighted by the level of enthusiasm and financial support from Sanofi and our existing investors as we scale from our existing clinical production to high-volume, large scale commercial manufacturing of our enFusetm drug delivery platform," said Michael D. Hooven, President and CEO of Enable Injections.

Biologics now comprise the majority of top selling medications and drugs in pharmaceutical company pipelines for treating numerous cancers, autoimmune diseases and genetic disorders. A large number of biologics now-a-days are required in doses exceeding 5mL. Their high volume and viscosity currently require costly, inconvenient intravenous (IV) administration.  Subcutaneous injection of biologics is the preferred delivery method, which is currently not as feasible without new technology, such as Enable enFuse.

Consequently, when biopharma companies want to make delivery of biologic doses of 5mL to 50mL more convenient for patients, they partner with Enable Injections to combine their drugs with the small body-worn, easy-to-use self-administration technology.  The alliances support product differentiation and the combination products are expected to improve compliance.

"Enable Injections has made significant progress and is now a clinical stage company with its initial products in human clinical trials," said John Rice, PhD, Enable Injections Board Member and CincyTech Director of Life Sciences.  "This financing will enable the company to advance to a commercial scale and bring its first products to market.  The investment and partnership with Sanofi provide that commercial validation."

About Enable Injections

A combination products company, Cincinnati, OH-based Enable Injections develops and manufactures wearable drug delivery devices that allow easy, comfortable patient self-administration of large volume/high viscosity drugs in doses from 5 mL to 50 mL. Enable's body-worn enFusetm drug delivery platform utilizes any standard container closure system, including syringes or vials; automatically warms and can automatically mix lyophilized solutions. Enable's devices are available for pharmaceutical and biotechnology industry investigational use. For more information please visit www.enableinjections.com and follow us on www.twitter.com/EnableInjection.

Media Contact:
KOGS Communication
Edna Kaplan
781-639-1910; 617-974-8659
[email protected]

Any original container closure can be used to fill Enable Injection's enFuse wearable large-volume drug delivery device - in seconds. Patients need only adhere the small biologics delivery device to their body and push one button, free to ambulate during treatment. The enFuse automatically warms and lyophilizes doses from 5mL to 50 mL as it fills - no waiting.

SOURCE Enable Injections


These press releases may also interest you

at 06:45
The "Global Pediatric Interventional Cardiology Market, Size, Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been added to  ResearchAndMarkets.com's offering. The Global Pediatric...

at 06:30
The "Sample Preparation Market by Product (Workstation, Instrument {Pipette, Washer, Centrifuge, Grinder}, Consumable {Kits, Filters, Plates}) Technique (Solid Phase Extraction, Purification) Application (Drug Discovery, Diagnostic) - Global Forecast...

at 06:15
The "Global Immune Health Supplements Market - Outlook & Forecast 2023-2028" report has been added to  ResearchAndMarkets.com's offering. The global immune health supplements market was valued at $20.80 billion in 2022 and is expected to reach...

at 06:08
ConTemporary Locums, a physician-focused medical staffing company, is ushering in a new era with a bold rebrand: Era Locums. This brand evolution marks a commitment to continued innovation and a deeper connection with the company's physician and...

at 06:05
AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize March 25-31 as National Physicians Week. This week and throughout the year, we celebrate the dedication of physicians who selflessly...

at 06:00
The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's...



News published on and distributed by: